NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced their planned presence at the American Society of Hematology (ASH) Annual Meeting and Exposition, including seven accepted abstracts for poster presentation and participation in the speaking session, “A New Era in Research: Pragmatic Prospective Real-World Studies.”.

纽约-（商业新闻）-Flatiron Health今天宣布计划参加美国血液学会（ASH）年会和博览会，其中包括七篇公认的摘要，用于海报展示和参加演讲会，“研究的新时代：实用的前瞻性现实世界研究”。

“At this year’s ASH Annual Meeting, Flatiron scientists and our collaborators are diving deeper into understanding how real-world patients with hematologic malignancies are being treated, the effectiveness of those strategies, and where there remains unmet need for novel, efficacious treatments,” said Jonathan Kish, VP, Research Sciences at Flatiron Health.

Flatiron Health Research Sciences副总裁乔纳森·基什（JonathanKish）表示：“在今年的ASH年会上，Flatiron科学家和我们的合作者正在深入了解现实世界中恶性血液病患者的治疗方法，这些策略的有效性，以及对新型有效治疗的需求尚未得到满足。”。

“By leveraging our high-quality real-world data at scale, coupled with our specialized in-house expertise, Flatiron is illuminating the oncology community's understanding of the biological and social determinants of patient outcomes to accelerate hematologic cancer research across the therapeutic development lifecycle.”.

“通过大规模利用我们高质量的真实世界数据，再加上我们专业的内部专业知识，Flatiron正在启发肿瘤学界对患者结局的生物学和社会决定因素的理解，以加速整个治疗开发生命周期中的血液癌症研究。”。

Highlights include:

亮点包括：

a poster presentation examining the impact of structural racism and social determinants of health (SDOH) on fluorescence in situ hybridization testing in patients with multiple myeloma, offering actionable guidance for specific SDOH factors that may have improved equity in multiple myeloma clinical trials..

海报展示研究了结构性种族主义和社会健康决定因素（SDOH）对多发性骨髓瘤患者荧光原位杂交检测的影响，为可能改善多发性骨髓瘤临床试验公平性的特定SDOH因素提供了可行的指导。。

a poster presentation providing evidence of improved survival outcomes for patients with Mantle Cell Lymphoma when treated with covalent Bruton’s tyrosine kinase inhibitors combined with an anti-CD20 antibody in the first-line setting.

海报展示提供了在一线环境中用共价布鲁顿酪氨酸激酶抑制剂联合抗CD20抗体治疗套细胞淋巴瘤患者时改善生存结果的证据。

a speaking session discussing how prospective real-world studies are using technology and data to address persistent issues in inefficient data collection, extended timelines, and a lack of diversity in patient populations.

演讲会讨论了前瞻性现实世界研究如何使用技术和数据来解决数据收集效率低下，时间表延长以及患者人群缺乏多样性等长期存在的问题。

Schedule a meeting with Flatiron Health at ASH 2024, and learn more about our abstracts and events, including workshops and panels.

安排与Flatiron Health在ASH 2024举行会议，了解更多关于我们的摘要和活动，包括研讨会和专题讨论会。

Follow Flatiron Health on Twitter and LinkedIn for more updates on #ASH24.

关注Twitter和LinkedIn上的Flatiron Health，了解更多关于#ASH24的更新。

Workshops & Panels

车间和面板

A New Era in Research: Pragmatic Prospective Real-World Studies

研究的新时代：语用前瞻性现实世界研究

Saturday, December 7 at 3:45 PM PT

12月7日星期六下午3:45 PT

Speakers:

发言人：

Majd Ghanim, MD, MSCR, Flatiron Health

然后是Ghanim，医学博士，MSCR，Flatiron Health

Poster Discussions and Presentations

海报讨论和演示

The Impact of Structural Racism and Social Determinants of Health on Fluorescence in Situ Hybridization Testing Among Patients with Multiple Myeloma

结构性种族主义和健康的社会决定因素对多发性骨髓瘤患者荧光原位杂交检测的影响

Amy E. Pierre, Gene Ho, Olive Mbha, Jingru Wang, Cleo A. Ryals

Poster Session: 906

海报环节：906

Poster Code: 3719

海报代码：3719

Real-World Characteristics and Survival Outcomes of Patients With Mantle Cell Lymphoma Treated With Covalent Bruton's Tyrosine Kinase Inhibitors in First-Line

共价布鲁顿酪氨酸激酶抑制剂一线治疗套细胞淋巴瘤患者的现实特征和生存结果

Ahmed Sawas, Niquelle Wadé, James Roose

艾哈迈德·萨瓦斯、尼克尔·韦德、詹姆斯·罗斯

Poster Session: 623

海报环节：623

Poster Code: 1655

海报代码：1655

Design and Methodological Considerations for Real World Data-Derived Progression-Free Survival in Multiple Myeloma

多发性骨髓瘤真实数据无进展生存期的设计和方法学考虑

Jocelyn R. Wang , Jennifer Hayden, Yiyang Yue, Craig S. Meyer, Ryan W. Gan, Youyi Zhang, Benjamin Ackerman, Pranay Mohanty, James Roose, Jennifer L. Lund, Sebastian Schneeweiss, Janick Weberpals, Omar Nadeem, Sikander Ailawadhi, Noopur S. Raje, Smith Giri, Juned Siddique, Laura Hester, Kelly Reid, Robin Carson, Khaled Sarsour, Ashita Batavia.

Jocelyn R.Wang、Jennifer Hayden、Yiyang Yue、Craig S.Meyer、Ryan W.Gan、Youyi Zhang、Benjamin Ackerman、Pranay Mohanty、James Roose、Jennifer L.Lund、Sebastian Schneeweiss、Janick Weberpals、Omar Nadeem、Sikander Ailawadhi、Noopur S.Raje、Smith Giri、Juned Siddique、Laura Hester、Kelly Reid、Robin Carson、Khaled Sarsour、Ashita Batavia。

Poster Session: 907

海报环节：907

Poster Code: 3762

海报代码：3762

Treatment Patterns and Predictors of Survival after First Line Therapy in Large B-Cell Lymphoma in a Real-World US Cohort

美国现实队列中大B细胞淋巴瘤一线治疗后的治疗模式和生存预测因素

Partners: Kite Pharma, University of Kansas Cancer Center, Central Care Cancer Center, Fred Hutchinson Cancer Research Center, Mosaic Life Care, Memorial Sloan Kettering Cancer Center

合作伙伴：Kite Pharma，堪萨斯大学癌症中心，中央护理癌症中心，弗雷德·哈钦森癌症研究中心，马赛克生命护理，纪念斯隆·凯特琳癌症中心

Joseph McGuirk, Mark Fesen, Scott Ramsey, Rony Abou-Jawde, Jeremy Snider, Blythe Adamson, Alexa Fu, Tony Proli, Hil Hsu, Anik R. Patel, Miguel-Angel Perales

约瑟夫·麦奎尔克（JosephMcGuirk）、马克·费森（Mark Fesen）、斯科特·拉姆齐（ScottRamsey）、罗尼·阿布·贾德（Rony Abou Jawde）、杰里米·斯奈德（Jeremy Snider）、布莱斯·亚当森（Blythe Adamson）、亚历克莎·福（Alexa Fu）、托尼·脯利（Tony Proli）、希尔·徐（Hi

Poster Session: 906

海报环节：906

Poster Code: 2367

海报代码：2367

Evaluating Reasons for Differences in Real-World (RW) Clinical Outcomes among Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) on Covalent BTK Inhibitors (cBTKis)

评估共价BTK抑制剂（cBTKis）复发/难治性套细胞淋巴瘤（R/R MCL）患者现实世界（RW）临床结局差异的原因

Partners: City of Hope, BeiGene, Fred Hutchinson Cancer Research Center, Mayo Clinic

合作伙伴：希望之城、贝金、弗雷德·哈钦森癌症研究中心、梅奥诊所

Tycel Phillips, Mengyang Di, Taavy A. Miller, Jingru Wang, Amy E. Pierre, Gregory A. Maglinte, Erlene K. Seymour, Yucai Wang

泰塞尔·菲利普斯、狄梦阳、塔维·米勒、王静茹、艾米·E·皮埃尔、格雷戈里·A·马格利特、埃琳·K·西摩、王育才

Poster Session: 906

海报环节：906

Poster Code: 3732

海报代码：3732

Real-World Outcomes of Acute Myeloid Leukemia Patients Undergoing Treatment with Tyrosine Kinase Inhibitor (TKI) therapy targeting FLT3, IDH1, or IDH2

接受针对FLT3，IDH1或IDH2的酪氨酸激酶抑制剂（TKI）治疗的急性髓系白血病患者的现实世界结局

Partners: O’Neal Comprehensive Cancer Center at University of Alabama Birmingham, University of Colorado School of Medicine

合作伙伴：阿拉巴马大学伯明翰分校奥尼尔综合癌症中心，科罗拉多大学医学院

Manuel Espinoza-Gutarra, Brooke Jarrett, Xiaoliang Wang, Anosheh Afghahi, Sejong Bae

Manuel Espinoza Gutarra、Brooke Jarrett、王晓亮、Anosheh Afghahi、Sejong Bae

Poster Session: 908

海报环节：908

Poster Code: 3808

海报代码：3808

A Real-World (RW) Analysis of the Relationship between Epstein-Barr Virus (EBV) Positivity and Baseline Characteristics, Treatment Patterns and Clinical Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL)

爱泼斯坦-巴尔病毒（EBV）阳性与弥漫性大B细胞淋巴瘤（DLBCL）基线特征，治疗模式和临床结局之间关系的现实世界（RW）分析

Partners: UT Southwestern Medical Center

合作伙伴：UT西南医学中心

Elif Yilmaz, Xiaoliang Wang, Niquelle Wadé, Yu-lun Liu, Praveen Ramakrishnan, Ahmed Sawas

伊里夫·伊尔马兹（Elif Yilmaz），王晓亮（Xiaoliang Wang），奈奎尔·瓦德（Niquelle Wadé），刘玉伦（Yu lun Liu），普拉文·拉马克里希南（Praveen Ramakrishnan），艾哈迈德·萨瓦斯

Poster Session: 906

海报环节：906

Poster Code: 3719

海报代码：3719

About Flatiron

关于扁钢

Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem.

Flatiron Health是一家healthtech公司，它扩大了肿瘤学护理点解决方案的可能性，并利用数据为每个癌症患者提供更智能的护理。通过机器学习和人工智能，现实世界的证据以及临床试验的突破，我们继续将患者的现实生活经验转化为知识，并创建一个更现代，相互关联的肿瘤学生态系统。

Flatiron Health is an independent affiliate of the Roche Group..

Flatiron Health是罗氏集团的独立附属公司。。